- Home
- SGMT vs IFRX Comparison
SGMT vs IFRX Comparison
Compare SGMT & IFRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGMT
- IFRX
- Stock Information
- Founded
- SGMT 2006
- IFRX 2007
- Country
- SGMT United States
- IFRX Germany
- Employees
- SGMT N/A
- IFRX N/A
- Industry
- SGMT
- IFRX Biotechnology: Pharmaceutical Preparations
- Sector
- SGMT
- IFRX Health Care
- Exchange
- SGMT Nasdaq
- IFRX Nasdaq
- Market Cap
- SGMT 71.2M
- IFRX 65.8M
- IPO Year
- SGMT 2023
- IFRX 2017
- Fundamental
- Price
- SGMT $3.26
- IFRX $1.61
- Analyst Decision
- SGMT Strong Buy
- IFRX Strong Buy
- Analyst Count
- SGMT 6
- IFRX 4
- Target Price
- SGMT $25.67
- IFRX $8.50
- AVG Volume (30 Days)
- SGMT 556.2K
- IFRX 259.7K
- Earning Date
- SGMT 05-08-2025
- IFRX 05-07-2025
- Dividend Yield
- SGMT N/A
- IFRX N/A
- EPS Growth
- SGMT N/A
- IFRX N/A
- EPS
- SGMT N/A
- IFRX N/A
- Revenue
- SGMT N/A
- IFRX $140,242.00
- Revenue This Year
- SGMT N/A
- IFRX $106.72
- Revenue Next Year
- SGMT N/A
- IFRX $66.89
- P/E Ratio
- SGMT N/A
- IFRX N/A
- Revenue Growth
- SGMT N/A
- IFRX 30.90
- 52 Week Low
- SGMT $1.73
- IFRX $0.82
- 52 Week High
- SGMT $7.38
- IFRX $2.82
- Technical
- Relative Strength Index (RSI)
- SGMT 52.50
- IFRX 59.72
- Support Level
- SGMT $3.19
- IFRX $1.42
- Resistance Level
- SGMT $3.45
- IFRX $1.68
- Average True Range (ATR)
- SGMT 0.31
- IFRX 0.18
- MACD
- SGMT 0.05
- IFRX 0.03
- Stochastic Oscillator
- SGMT 51.27
- IFRX 64.56
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.